CBD Medical Plays to Watch
May 22, 2019 -- InvestorsHub NewsWire -- via microcapspeculators.com --
No matter what your stance on CBD is, you should be able to see the
medical potential in the substance. GW Pharma did, and now
has the first FDA approved CBD product.
One company with FDA approval history and an exciting new CBD
product you should start researching right away is Innovus
Pharmaceuticals, Inc. (USOTC:
INNV). The company launched its
first hemp-derived Cannabidiol product with MZS Sleeping Aid™. With
Hemp being legal through the new Farm Bill, this makes companies
like INNV even more enticing.
The companies we’re highlighting today include:
Innovus Pharmaceuticals, Inc. (USOTC:
INNV), Aurora Cannabis, Inc. (NYSE:
ACB), ImmunoGen, Inc. (NASDAQ:
IMGN), GW Pharmaceuticals plc (NASDAQ:
GWPH), and Advaxis, Inc. (ADXS).
Innovus Pharmaceuticals, Inc. (USOTC:
INNV)
(Market Cap:
$5.162M;
Share Price:
$2.00), an emerging
commercial-stage pharmaceutical company that delivers safe,
innovative and effective over-the-counter medicine and consumer
care products to improve men’s and women's health and respiratory
diseases, has had quite the year:
- 2018 revenues of $24 million
- Q1 2019 Revenues of approximately $5.4 million, an
increase of $0.8 million or 18.0% compared to prior year and
$0.6 million or 12.8% compared to the prior quarter
- Sales & marketing expense as a percentage of total revenue
declined to 48.4% compared with 72.7% in prior year
- Annual product subscription and outbound concierge net revenue
of $1.1 million compared to $0.6 million in the prior year or a
98.2% increase
- Completed $3.17 million private placement
- Cash used in operations of $0.6 million compared with $0.7
million in the prior year
- Company's cash and merchant processor holdback position as of
May 13, 2019 was $2.9 million
- Annual 2019 net revenue projected to achieve record levels of
$26-28 million
2019 First Quarter and Recent Corporate Progress:
- Acquired assets of PrimeSavingsClub.com adding another revenue
channel with recent historical annual revenues of $2.5 million
- Diversified revenue channels resulting in approximately 30% of
revenue derived from e-commerce platforms
- Announced the FDA Approval of new ANDA for supply of FlutiCare
which provides the Company with two suppliers of the product and
the opportunity to use the dossier for international filings
- Obtained approval of four products: Diabasens®, BH®
Testosterone Booster, Xyralid® and RecalMax™ in Canada
- Completed reverse stock split with an intention to
potentially up list to Nasdaq
- International partner, Lavasta Pharma receives approval from
Algeria to market and sell Zestra® and Zestra Glide® and received a
purchase order for $186,000
- Announced a second partnered US ANDA for Minoxidil 5% Foam for
men and women to be sold under the name Regoxidine™
- Launched first hemp-derived Cannabidiol product with MZS
Sleeping Aid™.
“We are encouraged by our start to the 2019 year with
revenues increasing 18% and 12.8% in the comparable quarter in
the prior year and the previous quarter, respectively. The company
has been able to strategically diversify its revenue channels
during the quarter without significant disruption to overall
revenue and achieving revenues from e-commerce platforms by
approximately 30%. Additionally, with twelve products now approved
by Health Canada, we are poised to focus more marketing efforts in
Canada where we have historically experienced superior returns
which we believe will help us achieve our goal of profitability,”
stated Bassam Damaj, President and Chief Executive Officer of
Innovus Pharmaceuticals, Inc.
________
Aurora Cannabis, Inc. (NYSE:
ACB) (Market Cap: $8.902B; Share Price:
$8.66) reported a 20% jump in quarterly net revenue
on Tuesday, as Canada's legalization of recreational cannabis late
last year boosted demand.
The Edmonton, Alberta-based company's net revenue rose to C$65.2
million ($48.44 million) from C$54.2 million ($40.27 million) in
the second quarter ($1 = 1.3459 Canadian dollars).
________
ImmunoGen, Inc. (NASDAQ:
IMGN) (Market Cap:
$291.585M;
Share Price:
$1.95) plunged more than
30% on Wednesday after the company revealed that the U.S. Food and
Drug Administration has recommended further trials to "evaluate the
safety and efficacy" of one of its cancer-fighting
treatments. ImmunoGen said in statement that it had requested
a meeting with FDA officials to discuss the results of its Phase 3
FORWARD I trial and a potential path to registration for
mirvetuximab monotherapy - a treatment it has been developing for
patients with certain forms of ovarian cancer.
________
GW Pharmaceuticals plc (NASDAQ:
GWPH) (Market Cap: $5.662B; Share
Price: $184.35) announced that Justin Gover, GW’s
Chief Executive Officer, will present at the Bank of America
Merrill Lynch Healthcare Conference on Wednesday, May 15, 2019 at
8:00 a.m. PDT in Las Vegas.
________
Advaxis, Inc. (ADXS) (Market Cap: $23.137M; Share
Price: $2.89), a late-stage biotechnology company
focused on the discovery, development and commercialization of
immunotherapy products, today announced that the U.S. Food and Drug
Administration (FDA or Agency) has lifted the partial clinical hold
on AIM2CERV, the company’s Phase 3 clinical trial of axalimogene
filolisbac (AXAL) for the treatment of patients with high-risk
locally advanced cervical cancer. In its letter,
the FDA acknowledged that the company satisfactorily
addressed all hold questions.
Legal Disclaimer:
This article was written by Regal Consulting, LLC (“Regal
Consulting”). Regal Consulting has agreed to a three-month
term consulting agreement with Innovus Pharmaceuticals, Inc.
(USOTC:
INNV) signed 05/20/2019. The agreement calls for $20,000
in cash and 10,000 restricted 144 shares per month. All payments
were made directly by Innovus Pharmaceuticals,
Inc. to Regal Consulting, LLC to provide investor
relations services, of which this article is a part of. Regal
Consulting also paid one thousand dollars cash to
microcapspeculators.com to distribute this article. Regal
Consulting may have a position in the securities mentioned in this
article at the time of publication, and may increase or decrease
its position without notice. This article is based on public
information and the opinions of Regal Consulting. INNV was given an
opportunity to edit this article. This article contains
forward-looking statements that are subject to certain risks and
uncertainties that could cause actual results to differ materially
from any results predicted herein. Regal Consulting is not
registered with any financial or securities regulatory authority,
and does not provide or claim to provide investment advice.
http://www.regalconsultingllc.com/full
legal disclaimer/
Full Legal Disclaimer Click Here.
Contact Information:
Company Name: ACR Communication LLC.
Contact Person: Media Manager
Email: info@microcapspeculators.com
Phone: 1-702-720-6310
Country: United States
SOURCE: microcapspeculators.com
GW Pharmaceuticals (NASDAQ:GWPH)
Historical Stock Chart
From Aug 2024 to Sep 2024
GW Pharmaceuticals (NASDAQ:GWPH)
Historical Stock Chart
From Sep 2023 to Sep 2024